Pharmacy

Your Article Summary

See Latest Articles

Human genome sciences announces completion of enrollment in phase 2b monthly-dosing trial of albuferon
Human Genome Sciences, 06/22/09

Human Genome Sciences, Inc. announced that Novartis has completed enrollment and initial dosing in a Phase 2b clinical trial to evaluate the safety and efficacy of Albuferon administered monthly in combination with ribavirin in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

Today in Dosing...keeping you current

Receive free subspecialty "5-minute updates" via email

Congenital abnormalities in children of 43 pregnant women who attempted suicide with large doses of nitrazepam
Pharmacoepidemiology and Drug Safety, 12/09/09

Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers
British Journal of Clinical Pharmacology, 12/09/09

Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, 12/09/09

 See all of Dosing

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/10/09

Fyi from human genome sciences: gsk initiates second pivotal phase 3 trial for investigational cardiovascular medication darapladib
Human Genome Sciences, 12/10/09

Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09

 See all of Drug Trials